# First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct07284186/  
OnCo record `nct07284186` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of PLX-61639 run by Plexium, Inc., now recruiting.

## Summary

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors is a phase 1 interventional study registered as NCT07284186 by Plexium, Inc., with 155 participants planned, started 2025-12-01. Conditions recorded: Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Metastatic Solid Tumor, Non-Small Cell Lung Carcinoma, Esophageal Adenocarcinoma, SMARCA4 Mutation, Gastroesophageal Junction Squamous Cell Carcinoma and Advanced Solid Tumor. Interventions recorded: PLX-61639.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07284186
- Phase: 1
- Setting: A Phase 1, First-in-Human Study of the SMARCA2 Degrader, PLX-61639, in Patients With SMARCA4-Mutated Locally Advanced or Metastatic Solid Tumors
- Sponsor: Plexium, Inc.
- Enrolled: 155

## Sources

- ClinicalTrials.gov NCT07284186: https://clinicaltrials.gov/study/NCT07284186

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Oesophageal and junctional adenocarcinoma](https://onco.cc/cancers/oesophageal-adenocarcinoma/), [Oesophageal squamous cell carcinoma](https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/)
- drugs: [PLX-61639](https://onco.cc/drugs/plx-61639/)
- companies: [Plexium](https://onco.cc/companies/plexium/)

---
JSON: https://onco.cc/api/v1/entities/nct07284186.json